Sign Out
Use in Pregnancy: TIMOPTOL-XE has not been studied in human pregnancy. The use of TIMOPTOL-XE requires that the anticipated benefit be weighed against possible hazards.
While malformations have not been seen in epidemiological studies, they show a risk for foetal growth retardation when beta-blockers are administered by the oral route. In addition, symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If TIMOPTOL XE is administered until delivery, the neonate should be carefully monitored during the first days of life.
Nursing Mothers: Timolol is detectable in human milk. Because of the potential for serious adverse reactions from TIMOPTOL-XE in infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
